---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-031280"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T08:27:01.041467+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.82
calibrated_materiality_score: 0.82
confidence: "high"
source: SEC EDGAR
---

# Windtree Q3 net loss $4.4M ($0.86/share); cash $7.4M, runway to Q1 2024

## Summary
- Net loss of $4.4M ($0.86 per share) on 5.1M weighted-average shares; operating loss $4.7M.
- Cash and equivalents $7.4M as of Sep 30, expected to fund operations through Q1 2024.
- R&D expenses increased to $2.1M due to SEISMiC Extension study initiation; G&A stable at $2.6M.
- Entered new ATM agreement with Ladenburg for up to $2.05M stock sales; prior ATM terminated.
- Istaroxime program: SEISMiC Extension study underway; SCAI Stage C study expected to start Q4.

## SEC filing metadata
- accession: 0001437749-23-031280
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.82
- calibrated_materiality_score: 0.82
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/0001437749-23-031280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/wint20231108_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-031280
- JSON: https://secwatch.observer/filing/0001437749-23-031280.json
- Plain text: https://secwatch.observer/filing/0001437749-23-031280.txt

## Key facts
- Earnings Releases
  WINDTREE THERAPEUTICS INC /DE/ reported third quarter ended September 30, 2023 results: net income net loss of $4.4 million, EPS $0.86 per basic share.
  - Period: third quarter ended September 30, 2023
  - Net income: net loss of $4.4 million
  - EPS: $0.86 per basic share
  - Result: reported results
  source text: Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/0001437749-23-031280-index.htm
- Material Agreements
  WINDTREE THERAPEUTICS INC /DE/ entered into At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at up to $2,054,024 (effective 2023-11-09).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: up to $2,054,024
  - Effective: 2023-11-09
  source text: On November 9, 2023, Windtree Therapeutics, Inc. (the “ Company ”), entered into an At The Market Offering Agreement (the “ Sales Agreement ”) with Ladenburg Thalmann & Co. Inc. (“ Ladenburg ”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “ Shares ”), initially having an aggregate offering price of up to $2,054,024 through Ladenburg as agent and/or principal (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/0001437749-23-031280-index.htm
- Material Agreements
  WINDTREE THERAPEUTICS INC /DE/ terminated Prior At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. valued at terminated (effective 2023-11-09).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Ladenburg Thalmann & Co. Inc.
  - Value: terminated
  - Effective: 2023-11-09
  source text: On November 9, 2023, the Company and Ladenburg, in connection with entering into the Sales Agreement, jointly terminated the At The Market Offering Agreement, dated as of September 17, 2020, by and between the Company and Ladenburg (the “ Prior Sales Agreement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/946486/000143774923031280/0001437749-23-031280-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.